Ketamine's physiological effects

Ketamine (racemic or S-ketamine/esketamine) is a non-competitive NMDA receptor antagonist with rapid-acting antidepressant properties at subanesthetic doses, distinct from classic serotonergic psychedelics (psilocybin, LSD, etc.). It works primarily through glutamate surge, AMPA receptor activation, and downstream neuroplasticity (e.g., BDNF, synaptogenesis), rather than 5-HT2A agonism. This leads to different physiological profiles, subjective experiences (dissociative vs. mystical/ego-dissolving), duration (~45–70 minutes for subanesthetic effects vs. 4–8+ hours), and safety considerations.131

In psychiatric management (e.g., treatment-resistant depression/TRD, suicidal ideation), subanesthetic IV ketamine (typically 0.5 mg/kg) or FDA-approved esketamine nasal spray (Spravato) is used in supervised settings. Effects are acute and transient but can produce lasting neuroplastic changes. Below is a detailed breakdown of physiological effects, drawing from neuroimaging, EEG, cardiovascular studies, and reviews (data as of 2026).

Brain: Electrical Activity (EEG) and Blood Flow (CBF, fMRI, BOLD)

Ketamine alters cortical oscillations, functional connectivity, and hemodynamics in a dose- and region-dependent manner.

Electrical Activity (EEG/MEG):
- Prominent increase in gamma oscillations/power (high-frequency ~30–100 Hz) in prefrontal cortex (PFC) and hippocampus. These are linked to enhanced neural synchrony, cognitive processing, and antidepressant mechanisms (distinct from many other agents).128
- 3 Hz oscillations in the posteromedial cortex (PMC), associated with dissociative effects.
- Altered resting-state connectivity: Often decreases default mode network (DMN) connectivity; increases in some prefrontal-hippocampal or intraparietal connections. Effects are region-specific (e.g., decreased medial PFC connectivity in some human studies).
- Simultaneous EEG/fMRI: Increases BOLD signal in anterior cingulate cortex (ACC) and medial PFC during infusion.
Cerebral Blood Flow (CBF) and Neuroimaging:
- Generally increases global and regional CBF due to direct vasodilatory effects on cerebral vasculature (independent of NMDA on microvessels in some models).
- Subanesthetic doses (e.g., ~0.5 mg/kg IV): Focal/task-dependent BOLD changes; increases in dorsofrontal, cingulate, and insular areas in some phMRI studies. No major global task-independent CBF shifts in certain controlled paradigms, but overall perfusion often rises.140
- Contrasts with psilocybin (often decreases CBF in hubs like PCC/mPFC) but aligns more with LSD increases in some regions.
- Functional connectivity: Dose-dependent; can suppress or enhance specific networks. Repeated exposure may alter dopamine axon density (decreases in sensory areas, increases in cognitive/hypothalamic regions per preclinical data).

Therapeutic Relevance: Gamma increases and glutamatergic surge correlate with rapid antidepressant effects and neuroplasticity. Dissociative effects (tied to PMC oscillations) are common but often transient.

Heart: Electrical Activity (ECG) and Hemodynamics/Blood Flow

Ketamine is sympathomimetic at subanesthetic doses used in psychiatry.

Electrical (ECG) and Autonomic Effects:
- Increased heart rate (HR) and blood pressure (BP; systolic and diastolic rises of ~10–25 mmHg typical, peaking early in infusion).
- Via catecholamine release, norepinephrine reuptake inhibition, and central sympathetic stimulation.
- Transient; HR/BP usually return to baseline within 30–60+ minutes post-infusion.
- ECG: Indirect changes from HR/BP elevation; no consistent primary arrhythmogenic effects in healthy screened patients, but monitor for ischemia risk in vulnerable hearts.
Hemodynamics and Cardiac Output:
- Increased cardiac output and myocardial oxygen demand.
- At anesthetic doses: Can have direct negative inotropic effects that are usually overridden by sympathetic activation.
- Subanesthetic psychiatric doses: Generally well-tolerated but with measurable pressor effects.135

Risk Context: Effects are more pronounced in patients with hypertension, diabetes, or coronary artery disease (CAD). Rare reports of acute heart failure or electrophysiological issues in compromised individuals.

Other Organs and Systemic Effects

Respiratory System: Minimal respiratory depression at subanesthetic doses (a key advantage over many anesthetics). Preserves airway reflexes better; however, increased salivation/secretions possible. Airway compromise risk rises at higher/anesthetic doses.
Autonomic Nervous System: Dominant sympathetic activation (HR/BP rise, possible temperature or pupillary changes). Some studies note preserved or context-specific vagal influences.
Liver and Kidneys: Hepatic metabolism (primarily CYP3A4 and others); renal excretion of metabolites. Half-life ~2–3 hours (racemic ketamine). Monitor in severe hepatic/renal impairment.
Other: Possible anti-inflammatory effects in certain models; emergence phenomena (psychotomimetic/dissociative) at higher doses. Repeated/chronic use: Preclinical concerns about dopamine system remodeling.
Neuroimmune: Potential modulation of inflammation pathways (overlaps with some psychedelic research).

Contraindications and Safety in Psychiatric Management

Absolute/Strong Contraindications (differ from classic psychedelics):

Uncontrolled hypertension or severe cardiovascular disease (CAD, heart failure, recent events) — due to sympathomimetic pressor effects.
Increased intracranial pressure (historical concern).
Active psychosis or history of ketamine/substance abuse.
Pregnancy (limited data; potential risks).
Severe hepatic dysfunction.

Relative/Caution: Mild-moderate HTN (requires monitoring), diabetes, older age, or comorbid conditions. Psychotomimetic/dissociative side effects can be distressing but are usually transient.

Screening/Monitoring: Baseline vitals, ECG if indicated, continuous BP/HR during and after infusion (or supervised esketamine administration). Differs from psychedelics: Less emphasis on family psychosis history or specific interactions like lithium (no strong seizure signal); stronger focus on CV stability.137

Comparison to Classic Psychedelics (tying to prior discussion):

Mechanism: Glutamatergic (NMDA blockade + glutamate surge) vs. serotonergic (5-HT2A).
EEG: Gamma boost + specific dissociation-linked oscillations vs. broadband desynchronization and alpha/theta decreases.
CBF: Generally increases (vasodilatory) vs. variable (often decreases with psilocybin in hubs).
CV Profile: Reliable sympathomimetic increases in HR/BP vs. similar but sometimes milder/more variable effects.
Duration/Experience: Shorter, more internal/dissociative vs. longer, often visual/mystical.
Therapeutic: Both offer rapid antidepressant effects and neuroplasticity windows, but ketamine is more established in regulated clinical settings (IV clinics, Spravato). Classic psychedelics show promise in emerging trials but face different regulatory/access barriers.
Contraindications Overlap: CV disease, pregnancy, active psychosis are common concerns; ketamine has less emphasis on epilepsy or certain drug interactions.

Limitations and Context: Effects are dose-, route-, and individual-dependent. Subanesthetic psychiatric use has a favorable short-term safety profile in screened patients, but long-term data on repeated use (e.g., dopamine changes) continue to evolve. Dissociation can be therapeutically useful or challenging.

For your MindGuy MD telepsychiatry practice (men’s mental health, NJ patients), ketamine/esketamine represents a more immediately accessible evidence-based option for TRD compared to classic psychedelics in many jurisdictions. Rigorous screening (building on the contraindication frameworks we discussed) and supervised administration are essential. Both modalities highlight the value of rapid-acting, plasticity-promoting treatments.

If you’d like quantitative dosing protocols, patient selection criteria tailored to your practice, a side-by-side comparison table, content ideas (e.g., YouTube/blogs contrasting options for men’s depression), or deeper dives into specific studies/esketamine vs. racemic, let me know—I can refine this further! Always consult current guidelines and specialists for clinical decisions.